The Leading Source for Pharmaceutical & Biopharmaceutical Manufacturing News
FREE Daily Email Newsletter
Omnitronics Freeze Dryer
May 13, 2013 3:07 pm | Product Releases | CommentsThe VirTis Benchtop Pro with Omnitronics freeze dryer has been engineered with the research scientist in mind. Traditional time losses incurred from lengthy condenser defrost and clean-up procedures are minimized with the new hot-gas defrost facility on the BenchTop Pro.
Filtration and Drying Process
May 13, 2013 2:25 pm | Product Releases | CommentsThe simplefilter is designed for many pharmaceutical applications such as: hydrogenation, carbon filtration, catalyst recovery, pre-filter for micro-filtration, APIs and intermediate filtration.
Mixer/Dryer/Cooler
May 13, 2013 1:00 pm | Product Releases | CommentsThe Bella Series 543 mixer/dryer/cooler offers an improved method for drying or cooling powders, granulates and filter cakes. The Bella dryer can be used for drying, mixing, spraying, agglomerating and cooling in the same unit without additional equipment or costs.
Dry Powder Blending System
May 13, 2013 12:19 pm | Product Releases | CommentsThe blending system allows homogeneous blending of dry powder batches with its patented blending elements mounted to the inside of the container lid. The blending procedure can be scaled up from 4 – 12,000 liters.
Aptamer Protein Precipitation Kits
May 13, 2013 11:34 am | Product Releases | CommentsThe new range of Aptamer Protein Precipitation Kits bind with unmatched high specificity and affinity to target molecules. The new Aptoprecipitation (AP) / Co-aptoprecipitation (Co-AP) Kits are aptamer based protein precipitation kits designed to provide easy, quick and consistent protein precipitation.
Labor Drug Study Triggers Mommy-Blog Firestorm
May 13, 2013 8:49 am | Videos | CommentsA new study about a popular drug used to help so many moms speed up labor and could have some potentially negative effects. According to researchers, pitocin showed a potential link to some full term infants having increased admissions to neonatal intensive care units.
Government Stops Study Seeking To Prevent Type of Stroke
May 13, 2013 8:38 am | by LAURAN NEERGAARD,AP Medical Writer | News | CommentsThe government has halted a study testing treatments for a brain condition that can cause strokes after early results suggested invasive therapies were riskier than previously thought. The condition involves a kind of tangle in the brain called an arteriovenous malformation, or AVM. Arteries and veins grow knotted together until eventually some of them burst, causing a bleeding stroke.
FDA Accepts Biogen Idec’s BLA for Long-Lasting Factor VIII Therapy for Hemophilia A
May 13, 2013 8:31 am | News | CommentsBiogen Idec announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the marketing approval of ELOCTATE™ (recombinant factor VIII Fc fusion protein) for the treatment of hemophilia A.
Huge Drug Cost Disparities Seen in Health Overhaul
May 13, 2013 8:27 am | by RICARDO ALONSO-ZALDIVAR,Associated Press | News | CommentsCancer patients could face high costs for medications under President Barack Obama's health care law, industry analysts and advocates warn. Where you live could make a huge difference in what you'll pay. To try to keep premiums low, some states are allowing insurers to charge patients a hefty share of the cost for expensive medications used to treat cancer, multiple sclerosis, rheumatoid arthritis and other life-altering chronic diseases.
Frazier Healthcare Acquires AndersonBrecon from AmerisourceBergen
May 13, 2013 8:17 am | News | CommentsFrazier Healthcare and Packaging Coordinators, Inc. today announced that they have completed the acquisition of pharmaceutical packager AndersonBrecon from its parent company AmerisourceBergen Corporation. AndersonBrecon will now merge with and operate as Packaging Coordinators, Inc.
Elan Enters $1B Royalty Deal with Theravance
May 13, 2013 8:12 am | by The Associated Press | News | CommentsIrish drugmaker Elan plans to pay $1 billion for the right to future royalties from four respiratory treatments being developed by Theravance and GlaxoSmithKline. The deal will give Elan 21 percent of the future royalties that Theravance Inc. receives from Glaxo. Theravance shares jumped 7 percent in premarket trading. Elan shares slipped.
FDA Denies Request to Block Generic Painkiller
May 10, 2013 5:53 pm | by The Associated Press | News | CommentsIn a surprise move Friday, federal health regulators denied a request by Endo Health Solutions to block generic versions of its painkiller Opana ER, which the company argued are more easily abused than its branded product. Endo's Opana ER is a long-acting narcotic drug used to treat moderate and...
Actavis, Warner Chilcott Discussing Combination
May 10, 2013 3:38 pm | by MARLEY SEAMAN - AP Business Writer - Associated Press | News | CommentsThe drugmakers Actavis Inc. and Warner Chilcott PLC say they are holding early discussions about a possible combination of the two companies. The companies say there is no guarantee that Actavis will make an offer for Warner Chilcott, however. Actavis expects to generate more than $8.1 billion...
Warner Chilcott 1Q Net Income Holds Steady
May 10, 2013 1:07 pm | by The Associated Press | News | CommentsIrish drugmaker Warner Chilcott PLC said Friday its net income held steady in the first quarter despite lower sales of some of its biggest products. The company said sales of its ulcerative colitis drug Asacol fell because it stopped selling one dose of the drug after receiving marketing approval...
Medical Experiment May Give Old Hearts a New Life
May 10, 2013 12:28 pm | by CBS | Videos | CommentsDoctors have seen promising results in an experiment that transfers a hormone from healthy mice to mice with heart failure. The hormone, GDF11, declines with age in mice, and the scientists took GDF11 from young, healthy mice giving it to old mice with heart failure. Dr. Jon LaPook reports the team's next step is to see if it has the same effect in humans.
